Pharvaris (PHVS) Net Equity Issued and Repurchased (2020 - 2025)

Pharvaris (PHVS) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $200.3 million in Q3 2025.

• Quarterly Net Equity Issued and Repurchased rose 17806.98% year-over-year to $200.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $201.5 million (up 100.0% YoY) and the FY2022 annual result came in at $10.1 million, down 94.54% from the prior year.
• Net Equity Issued and Repurchased improved to $200.3 million in Q3 2025, from $418.83 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $200.3 million in Q3 2025 to a low of -$69762.2 billion in Q3 2023.
• A 5-year average of -$5366.3 billion and a median of $97449.6 in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased sank 315574464166.85% — and 2025, when it soared 17806.98%.
• Tracing PHVS's Net Equity Issued and Repurchased over 5 years: stood at -$470309.3 in 2021, then surged by 104.7% to $22106.4 in 2022, then slumped by 315574464166.85% to -$69762.2 billion in 2023, then surged by 100.0% to $1.1 million in 2024, then soared by 17806.98% to $200.3 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $200.3 million (Q3 2025), $418.83 (Q2 2025), and $30597.2 (Q1 2025), per Business Quant data.